Evidence map›Paper›PMID 26467999›Full record

ArticleJournal of the American Heart Association2015

Racial Disparities in Intravenous Recombinant Tissue Plasminogen Activator Use Persist at Primary Stroke Centers.

Hugo J Aparicio, Brendan G Carr, Scott E Kasner, Michael J Kallan, Karen C Albright, Dawn O Kleindorfer, Michael T Mullen

Abstract readComparative Study
In one paragraph

Article in Journal of the American Heart Association, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Racial and Ethnic Disparities in Stroke Incidence and Outcomes.Current cardiovascular risk reports · 2025
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Observational
  13. Article
  14. Article
  15. Article
  16. Racial and Ethnic Disparities in Stroke Reperfusion Therapy in the USA.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2023
    Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hugo J AparicioDepartment of Neurology, Boston University, Boston, MA (H.J.A.) Department of Neurology, University of Pennsylvania, Philadelphia, PA (H.J.A., S.E.K., M.T.M.).
Brendan G CarrDepartment of Emergency Medicine, Thomas Jefferson University, Philadelphia, PA (B.G.C.).
Scott E KasnerDepartment of Neurology, University of Pennsylvania, Philadelphia, PA (H.J.A., S.E.K., M.T.M.).
Michael J KallanCenter for Clinical Epidemiology & Biostatistics, University of Pennsylvania, Philadelphia, PA (M.J.K.).
Karen C AlbrightHealth Services and Outcomes Research Center for Outcome and Effectiveness Research and Education, University of Alabama at Birmingham, AL (K.C.A.) Center of Excellence in Comparative Effectiveness Research for Eliminating Disparities/Minority Health & Health Disparities Research Center, University of Alabama at Birmingham, AL (K.C.A.) Department of Epidemiology, University of Alabama at Birmingham, AL (K.C.A.).
Dawn O KleindorferDepartment of Neurology, University of Cincinnati, OH (D.O.K.).
Michael T MullenDepartment of Neurology, University of Pennsylvania, Philadelphia, PA (H.J.A., S.E.K., M.T.M.) Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, PA (M.T.M.).

Funding

VCID and Stroke in a Bi-racial National CohortU01NS041588 · NINDS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI CUSHMAN, MARY, HOWARD, GEORGE · 2002 to 2022
$96.0M
RESEARCH TRAINING COREP60MD000502 · NIMHD · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI FOUAD, MONA N. · 2003 to 2016
$16.2M
UAB Health Services Research (HSR) Training ProgramT32HS013852 · AHRQ · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI LEVITAN, EMILY B, MUGAVERO, MICHAEL J · 2003 to 2024
$8.0M
Research career training in vascular medicineK12HL083772 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI MOHLER, EMILE R. · 2007 to 2012
$3.1M
Optimization modeling and comparative effectiveness of regionalized stroke careR01HS018362 · AHRQ · UNIVERSITY OF PENNSYLVANIA · PI BRANAS, CHARLES C. · 2010 to 2013
$1.8M
The comparative effectiveness of time-adjusted trauma center care on mortalityK08HS017960 · AHRQ · UNIVERSITY OF PENNSYLVANIA · PI CARR, BRENDAN G · 2009 to 2013
$760k
AHRQ HHS K08HS17960AHRQ HHS R01 HS018362AHRQ HHS T32 HS013852AHRQ HHS T32 HS013852-10NHLBI NIH HHS K12 HL083772NIMHD NIH HHS P60 MD000502-08S1NINDS NIH HHS U01NS041588
6 · The paper itself

Abstract

backgroundPrimary stroke centers (PSCs) utilize more recombinant tissue plasminogen activator (rt-PA) than non-PSCs. The impact of PSCs on racial disparities in rt-PA use is unknown. METHODS AND

resultsWe used data from the Nationwide Inpatient Sample from 2004 to 2010, limited to states that publicly reported hospital identity and race. Hospitals certified as PSCs by The Joint Commission were identified. Adults with a diagnosis of ischemic stroke were analyzed. Rt-PA use was defined by the International Classification of Diseases, 9th Revision procedure code 99.10. Discharges (304 152 patients) from 26 states met eligibility criteria, and of these 71.5% were white, 15.0% black, 7.9% Hispanic, and 5.6% other. Overall, 24.7% of white, 27.4% of black, 16.2% of Hispanic, and 29.8% of other patients presented to PSCs. A higher proportion received rt-PA at PSCs than non-PSCs in all race/ethnic groups (white 7.6% versus 2.6%, black 4.8% versus 2.0%, Hispanic 7.1% versus 2.4%, other 7.2% versus 2.5%, all P<0.001). In a multivariable model adjusting for year, age, sex, insurance, medical comorbidities, a diagnosis-related group-based mortality risk indicator, ZIP code median income, and hospital characteristics, blacks were less likely to receive rt-PA than whites at non-PSCs (odds ratio=0.58, 95% CI 0.50 to 0.67) and PSCs (odds ratio=0.63, 95% CI 0.54 to 0.74) and Hispanics were less likely than whites to receive rt-PA at PSCs (odds ratio=0.77, 95% CI: 0.63 to 0.95). In the fully adjusted model, interaction between race and presentation to a PSC for likelihood of receiving rt-PA did not reach significance (P=0.98).

conclusionsRacial disparities in intravenous rt-PA use were not reduced by presentation to PSCs. Black patients were less likely to receive thrombolytic treatment than white patients at both non-PSCs and PSCs. Hispanic patients were less likely to be seen at PSCs relative to white patients and were less likely to receive intravenous rt-PA in the fully adjusted model.

Indexed as

Black or African AmericanHealth Services AccessibilityHispanic or LatinoWhite PeopleAdministration, IntravenousAdolescentAdultAgedChi-Square DistributionDatabases, FactualFemaleFibrinolytic AgentsHealthcare DisparitiesHealth PolicyHumansMaleFibrinolytic AgentsRecombinant ProteinsTissue Plasminogen Activatorhealth disparitieshealth policystrokestroke carethrombolysis

Identifiers

PMID26467999
PMCPMC4845141

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.